EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tacrolimus Trough Concentration‐Escalating Bipartite Therapy (Glucocorticoids Combined With Tacrolimus) for Refractory MDA5 Antibody‐Positive Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Pneumonia

Anji Xiong iD, Jiang Shao, Yanzao Zhao, Xuemei Huang, Jie Luo, Xi He, Pu Chen, Yiman Ye, Chuanmei Xie, Xin Wei, Xiongyan Luo

Immunity, Inflammation and Disease · 2025

DOI: 10.1002/iid3.70295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2025. Verfasst von Anji Xiong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Neijiang, Sichuan, China. Hauptthemen laut MEDLINE: Dermatomyositis, Lung Diseases, Interstitial, Interferon-Induced Helicase, IFIH1, Tacrolimus. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by the Government and School Cooperation Program of Nanchong, Sichuan, China [grant number 22JCYJPT0027]..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to determine the outcomes of patients that have refractory anti‐melanoma differentiation‐associated gene 5 ( MDA5 ) antibody‐positive clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia treated with tacrolimus trough concentration‐escalating bipartite therapy (glucocorticoids combined with tacrolimus).

Methods

We retrospectively enrolled 19 patients that had refractory anti‐ MDA5 antibody‐positive clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonitis who were unable to achieve disease control on intensive combination immunosuppressive therapy with glucocorticoids and immunosuppressive agents. They were treated with tacrolimus trough concentration‐escalating bimodal therapy. Patients receiving tacrolimus trough concentration‐escalating dual therapy were selected based on poor prognostic factors and refractoriness to the initial immunosuppressive therapy.

Results

The 19 patients included in the study were treated with tacrolimus trough concentration‐escalating bipartite therapy (glucocorticoids combined with tacrolimus) immediately after diagnosis of refractory anti‐melanoma differentiation‐associated gene 5 ( MDA5 ) antibody‐positive clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia. Following 17 months of treatment and subsequent follow‐up, 16 patients displayed decreased ferritin and lactate dehydrogenase levels and improved oxygenation index and high‐resolution lung computed tomography findings. Two patients died, and one patient (case 9) developed renal impairment on Day 14 of treatment. Renal damage occurred when the tacrolimus trough concentration was 15.68 ng/mL. After lowering the tacrolimus trough concentration, the patient′s renal function gradually normalized. However, because of the addition of cyclophosphamide due to disease activity, the patient did not experience the full efficacy of the two‐combination therapy. Tacrolimus‐associated renal impairment and viral and fungal infections occurred in some patients treated with bimodal therapy, but it did not have serious consequences.

Conclusion

For patients with refractory anti‐ MDA5 antibody‐positive clinically amyopathic dermatomyositis associated with rapidly progressive interstitial pneumonia, the combination of glucocorticoids and tacrolimus is a potentially effective treatment regimen. However, there is considerable individual variation in the optimal trough concentration of tacrolimus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisLung Diseases, InterstitialInterferon-Induced Helicase, IFIH1TacrolimusImmunosuppressive AgentsGlucocorticoidsHumansFemaleMaleMiddle AgedRetrospective StudiesAdultDrug Therapy, CombinationAutoantibodiesAgedTreatment OutcomeDisease Progression

Stichwörter der Autor:innen

MDA‐5dermatomyositisinterstitial pneumoniatacrolimustreatment

Substanzen

Interferon-Induced Helicase, IFIH1TacrolimusIFIH1 protein, humanImmunosuppressive AgentsGlucocorticoidsAutoantibodies

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Neijiang, Sichuan, China.
  • Department of Rheumatology and Immunology, Beijing Anzhen Nanchong Hospital, Capital Medical University & Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong, S…
  • Department of Rheumatology and Immunology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
  • Department of Rheumatology and Immunology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
  • Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

ORCID-Profile: Anji Xiong

Förderung

  • This study was supported by the Government and School Cooperation Program of Nanchong, Sichuan, China [grant number 22JCYJPT0027].

Zitieren

APA

Xiong, A., Shao, J., Zhao, Y., Huang, X., Luo, J., He, X., Chen, P., Ye, Y., Xie, C., Wei, X., & Luo, X. (2025). Tacrolimus Trough Concentration‐Escalating Bipartite Therapy (Glucocorticoids Combined With Tacrolimus) for Refractory MDA5 Antibody‐Positive Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Pneumonia. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70295

Vancouver

Xiong A, Shao J, Zhao Y, Huang X, Luo J, He X, et al. Tacrolimus Trough Concentration‐Escalating Bipartite Therapy (Glucocorticoids Combined With Tacrolimus) for Refractory MDA5 Antibody‐Positive Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Pneumonia. Immunity, Inflammation and Disease. 2025. doi:10.1002/iid3.70295

BibTeX
@article{Xiong2025,
  author = {Xiong, Anji and Shao, Jiang and Zhao, Yanzao and Huang, Xuemei and Luo, Jie and He, Xi and Chen, Pu and Ye, Yiman and Xie, Chuanmei and Wei, Xin and Luo, Xiongyan},
  title = {Tacrolimus Trough Concentration‐Escalating Bipartite Therapy (Glucocorticoids Combined With Tacrolimus) for Refractory MDA5 Antibody‐Positive Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Pneumonia},
  journal = {Immunity, Inflammation and Disease},
  year = {2025},
  doi = {10.1002/iid3.70295}
}
Kostenlos starten →